Advertisement

Journal of Neurology

, Volume 251, Supplement 6, pp vi28–vi32 | Cite as

Dementia in idiopathic Parkinson’s syndrome

  • Gerd A. FuchsEmail author
  • Irene Gemende
  • Birgit Herting
  • Matthias R. Lemke
  • Christian Oehlwein
  • Heinz Reichmann
  • Jürgen Rieke
  • David Emmans
  • Jens Volkmann
WORKSHOP 2

Abstract.

Approximately 25% of patients with idiopathic Parkinson’s disease (IPD) later developdementia, with the typical characteristics as detailed in ICD-10 and DSM-IV. Differential diagnosis has to exclude dementia due to Lewy bodies, subcortical vascular encephalopathy and subcortical dementia due to progressive supranuclear paralysis or corticobasal degeneration. Several studies showed promising results for cholinesterase inhibitors such as donepezile, rivastigmine and galantamine. The demented Parkinsonian patients then present with improvement in cognitive function while motor skills do not deteriorate.

Key words

dementia Parkinson’s disease Lewy body dementia cholinesterase inhibitor 

References

  1. 1.
    Aarsland D, Tandberg E, Larsen JP, Cummings JL (1996) Frequency of dementia in Parkinson disease. Arch Neurol 53:538–542PubMedGoogle Scholar
  2. 2.
    Aarsland D, Laake K, Larsen JP, Janvin C (2002) Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 72:708–712CrossRefPubMedGoogle Scholar
  3. 3.
    Aarsland D, utchinson M, Larsen JP (2003) Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int J Geriatr Psychiatry 18:937–941CrossRefPubMedGoogle Scholar
  4. 4.
    Berger F, Sramko C, Baas H, Fuchs G, Reichmann H (2000) Donepezil in the treatment of patients with concomitant Alzheimer’s disease and Parkinson’s disease: results from a post marketing surveillance study. Movement Disorders (Suppl 3):129Google Scholar
  5. 5.
    Braak H, Braak E (1994) Dementia in diseases of the extra-pyramidal motor system. Über den dementiellen Abbau bei Erkrankungen des extrapyramidalmotorischen Systems. In: Huffmann G, Braune HJ, Henn KH (eds) Extrapyramidal-motorische Erkrankungen. Einhorn-Presse, pp 81–88Google Scholar
  6. 6.
    Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD (2003) Rivastigmine (Exelon) for dementia in patients with Parkinson’s disease. Acta Neurol Scand 108:368–373CrossRefPubMedGoogle Scholar
  7. 7.
    Hegemann-Richard I, Papka M, Rubio A, Kurlan R (2002) Parkinson’s disease and dementia with Lewy bodies: one disease or two? Mov Disord 17:1161–1165CrossRefPubMedGoogle Scholar
  8. 8.
    Henneberg A (1999) Cognitive dysfunction in Parkinson’s disease—(Parkinson-plus dementia)—Successful treatment by donepezile (Aricept ®). Presented at: Mental dysfunction in Parkinson’s disease. AmsterdamGoogle Scholar
  9. 9.
    Hutchinson M, Fazzini E (1996) Cholinesterase inhibition in Parkinson’s disease. J Neurol Neurosurg Psychiatry 61:324–325Google Scholar
  10. 10.
    Jagust WJ, Reed BR, Martin EM, Eberling JL, Nelson-Abbott RA (1992) Cognitive function and regional cerebral blood flow in Parkinson’s disease. Brain 115:521–537PubMedGoogle Scholar
  11. 11.
    Kogan E, Henneberg AE (2000) Parkinson-plus-dementia-syndrome—successful treatment by rivastigmine. J Neural Transm 107:I–LIGoogle Scholar
  12. 12.
    Korczyn AD, Shabati H, Benbunan B, et al. (2001) The effect of treatment with rivastigmine (Exelon) on cognitive functions of patients with dementia and Parkinson’s disease. Parkinsonism Relat Disord 7:S61Google Scholar
  13. 13.
    McKeith IG, Galasko D, Kosaka K, Perry E, Dickson D, Hansel L (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB). Neurology 47:1113–1124PubMedGoogle Scholar
  14. 14.
    McKeith IG, Perry EK, Perry RH (1999) Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 53:902–905PubMedGoogle Scholar
  15. 15.
    McKeith IG, Del Ser T, Spano P, et al. (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356:2031–2036CrossRefPubMedGoogle Scholar
  16. 16.
    Samuel W, Caligiuri M, Galasko D, et al. (2000) Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 15:794–802CrossRefPubMedGoogle Scholar
  17. 17.
    Shea C, MacKnight C, Rockwood K (1998) Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 10:229–238CrossRefPubMedGoogle Scholar
  18. 18.
    Turjanski N, Brooks DJ (1997) PET and the investigation of dementia in the parkinsonian patient. J Neurol Transm (Suppl)51:37–48Google Scholar
  19. 19.
    Van Zagten M, Lodder J, Kessels F (1998) Gait disorder and parkinsonian signs in patients with stroke related to small deep infarcts and white matter lesions. Mov Disord 13:89–95PubMedGoogle Scholar

Copyright information

© Steinkopff Verlag 2004

Authors and Affiliations

  • Gerd A. Fuchs
    • 1
    Email author
  • Irene Gemende
    • 1
  • Birgit Herting
    • 1
  • Matthias R. Lemke
    • 1
  • Christian Oehlwein
    • 1
  • Heinz Reichmann
    • 1
  • Jürgen Rieke
    • 1
  • David Emmans
    • 1
  • Jens Volkmann
    • 1
  1. 1.Parkinson-Clinic WolfachWolfachGermany

Personalised recommendations